OBJECTIVE: The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. METHODS: The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales. RESULTS: Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms (U = 25.5; P = 0.028; r = -0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%). CONCLUSION: The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS.
OBJECTIVE: The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. METHODS: The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales. RESULTS: Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms (U = 25.5; P = 0.028; r = -0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%). CONCLUSION: The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS.
Authors: Michael Riedel; M J Schwarz; M Strassnig; I Spellmann; A Müller-Arends; K Weber; J Zach; N Müller; H J Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-11-29 Impact factor: 5.270
Authors: David A Shapiro; Sean Renock; Elaine Arrington; Louis A Chiodo; Li-Xin Liu; David R Sibley; Bryan L Roth; Richard Mailman Journal: Neuropsychopharmacology Date: 2003-05-21 Impact factor: 7.853
Authors: Robert L Findling; Ralph E Kauffman; Floyd R Sallee; William H Carson; Margaretta Nyilas; Suresh Mallikaarjun; Susan E Shoaf; Robert A Forbes; David W Boulton; Andrei Pikalov Journal: J Clin Psychopharmacol Date: 2008-08 Impact factor: 3.153
Authors: Wolfgang Aichhorn; Josef Marksteiner; Thomas Walch; Gerald Zernig; Hartmann Hinterhuber; Christoph Stuppaeck; Georg Kemmler Journal: J Child Adolesc Psychopharmacol Date: 2007-10 Impact factor: 2.576
Authors: Christian J Bachmann; Anette Rieger-Gies; Monika Heinzel-Gutenbrunner; Christoph Hiemke; Helmut Remschmidt; Frank M Theisen Journal: Ther Drug Monit Date: 2008-08 Impact factor: 3.681
Authors: Sanjiv Kumra; Joel V Oberstar; Linmarie Sikich; Robert L Findling; Jon M McClellan; Sophia Vinogradov; S Charles Schulz Journal: Schizophr Bull Date: 2007-10-08 Impact factor: 9.306